Analysts expect Spark Therapeutics, Inc. (NASDAQ:ONCE) to post ($1.91) earnings per share for the current fiscal quarter, according to Zacks. Five analysts have issued estimates for Spark Therapeutics’ earnings, with the highest EPS estimate coming in at ($1.75) and the lowest estimate coming in at ($2.05). Spark Therapeutics posted earnings of ($1.07) per share during the same quarter last year, which suggests a negative year over year growth rate of 78.5%. The business is scheduled to issue its next quarterly earnings results on Thursday, November 2nd.

On average, analysts expect that Spark Therapeutics will report full year earnings of ($7.36) per share for the current year, with EPS estimates ranging from ($8.00) to ($6.77). For the next fiscal year, analysts expect that the business will post earnings of ($5.25) per share, with EPS estimates ranging from ($7.92) to ($3.01). Zacks’ earnings per share averages are a mean average based on a survey of sell-side research analysts that cover Spark Therapeutics.

Spark Therapeutics (NASDAQ:ONCE) last released its quarterly earnings data on Wednesday, August 2nd. The biotechnology company reported ($1.89) earnings per share for the quarter, missing the consensus estimate of ($1.75) by $0.14. The firm had revenue of $1.48 million during the quarter, compared to the consensus estimate of $1.33 million. Spark Therapeutics had a negative net margin of 962.72% and a negative return on equity of 59.74%. The business’s revenue was up 14.7% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($1.04) earnings per share.

Several equities analysts recently issued reports on the company. Jefferies Group LLC assumed coverage on Spark Therapeutics in a research note on Monday, July 10th. They set a “buy” rating and a $85.00 target price on the stock. Cantor Fitzgerald set a $94.00 target price on Spark Therapeutics and gave the stock a “buy” rating in a research note on Monday, July 17th. ValuEngine lowered Spark Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 20th. BidaskClub raised Spark Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, June 22nd. Finally, Zacks Investment Research raised Spark Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Wednesday, July 19th. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and twelve have assigned a buy rating to the company’s stock. Spark Therapeutics presently has an average rating of “Buy” and an average price target of $82.27.

In other Spark Therapeutics news, CFO Stephen W. Webster sold 7,663 shares of the stock in a transaction dated Monday, June 19th. The stock was sold at an average price of $60.00, for a total value of $459,780.00. Following the sale, the chief financial officer now owns 10,163 shares of the company’s stock, valued at approximately $609,780. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Jeffrey D. Marrazzo sold 28,650 shares of the stock in a transaction dated Wednesday, August 2nd. The shares were sold at an average price of $80.01, for a total value of $2,292,286.50. Following the completion of the sale, the chief executive officer now directly owns 258,650 shares in the company, valued at approximately $20,694,586.50. The disclosure for this sale can be found here. Insiders sold a total of 314,310 shares of company stock worth $21,866,838 in the last ninety days. 7.30% of the stock is owned by corporate insiders.

A number of large investors have recently bought and sold shares of ONCE. FMR LLC raised its stake in Spark Therapeutics by 0.9% in the first quarter. FMR LLC now owns 4,656,655 shares of the biotechnology company’s stock worth $248,386,000 after buying an additional 40,698 shares in the last quarter. BlackRock Inc. raised its stake in Spark Therapeutics by 11,332.0% in the first quarter. BlackRock Inc. now owns 1,840,214 shares of the biotechnology company’s stock worth $98,158,000 after buying an additional 1,824,117 shares in the last quarter. Vanguard Group Inc. raised its stake in Spark Therapeutics by 5.2% in the first quarter. Vanguard Group Inc. now owns 1,827,660 shares of the biotechnology company’s stock worth $97,487,000 after buying an additional 90,686 shares in the last quarter. JPMorgan Chase & Co. raised its stake in Spark Therapeutics by 7.8% in the first quarter. JPMorgan Chase & Co. now owns 1,549,093 shares of the biotechnology company’s stock worth $82,628,000 after buying an additional 112,596 shares in the last quarter. Finally, Wellington Management Group LLP raised its stake in Spark Therapeutics by 119.5% in the first quarter. Wellington Management Group LLP now owns 808,782 shares of the biotechnology company’s stock worth $43,140,000 after buying an additional 440,287 shares in the last quarter. 88.96% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION NOTICE: This news story was published by American Banking News and is the sole property of of American Banking News. If you are accessing this news story on another site, it was copied illegally and reposted in violation of United States and international copyright and trademark law. The correct version of this news story can be read at https://www.americanbankingnews.com/2017/08/06/1-91-eps-expected-for-spark-therapeutics-inc-nasdaqonce-this-quarter.html.

Spark Therapeutics (NASDAQ:ONCE) traded up 0.14% during mid-day trading on Friday, hitting $76.96. The company had a trading volume of 2,519,357 shares. The company’s market capitalization is $2.38 billion. The company has a 50-day moving average price of $63.15 and a 200 day moving average price of $58.70. Spark Therapeutics has a 52-week low of $35.07 and a 52-week high of $78.08.

About Spark Therapeutics

Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.

Get a free copy of the Zacks research report on Spark Therapeutics (ONCE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Spark Therapeutics (NASDAQ:ONCE)

Receive News & Ratings for Spark Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.